Outcomes of Allogeneic Stem Cell Transplant (allo-SCT) Recipients in the Era of Newer Antifungal Agents

Nisha N. Shah, Emory University
Ajay Nooka, Emory University
Sagar Lonial, Emory University
H Jean Khoury, Emory University
Edmund K Waller, Emory University
Amelia A Langston, Emory University

Journal Title: Online Journal of Public Health Informatics
Volume: Volume 6, Number 1
Publisher: University of Illinois at Chicago Library | 2014, Pages e56-e56
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.5210/ojphi.v6i1.5143
Permanent URL: http://pid.emory.edu/ark:/25593/ghrfk

Final published version: http://journals.uic.edu/ojs/index.php/ojphi/article/view/5143

Copyright information:
This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), which permits distribution, public display, and publicly performance, making multiple copies, distribution of derivative works, provided the original work is properly cited. This license requires copyright and license notices be kept intact, credit be given to copyright holder and/or author. This license prohibits exercising rights for commercial purposes.

Accessed April 7, 2018 2:49 AM EDT
Outcomes of Allogeneic Stem Cell Transplant (allo-SCT) Recipients in the Era of Newer Antifungal Agents

Nishi Shah*2, 1, Ajay K. Nooka1, Sagar Lonial1, Hannah J. Khoury1, Edmund Waller1 and Amelia Langston1

1Winship Cancer Institute, Emory University, Atlanta, GA, USA; 2Rollins School of Public Health, Emory University, Atlanta, GA, USA

Introduction
Fungal infections (FI) are a leading cause of morbidity and mortality among patients undergoing allo-SCT. The newer anti-fungal agents, the echinocandins and extended spectrum azoles, have offered alternatives to Amphotericin B and fluconazole. Data from large patient samples evaluating the magnitude of benefit with the newer anti-fungal agents are lacking. We analyzed the Nationwide Inpatient Sample (NIS) database from Healthcare Cost and Utilization Project to evaluate the trends in the incidence of FI and to evaluate the potential impact of newer anti-fungal agents on in-hospital mortality (IHM) among allo-SCT recipients.

Methods
We used the NIS database to obtain the inpatient data of adults admitted for primary procedures of allo-SCT between 01/2000 until 12/2010. We have evaluated trends of various FI in this patient population. We performed multivariate logistic regression analyses to evaluate the risk factors for IHM in allo-SCT pts. The occurrence of FI, the era of antifungal therapy (2000-2001 vs. 2002-2010), gender, payer status, and length of hospital stay (> median) were the variables used for the analyses. Lastly, we performed separate multivariate logistic regression analyses for 2000-2001 and 2002-2010 data to evaluate the difference in association of FI with IHM in allo-SCT pts.

Results
The incidence of invasive candidiasis, zygomycosis and other fungal infections (include histoplasmosis, coccidioidomycosis, allescheriosis, blastomycosis, paracoccidioidomycosis, lobomyositis, pneumocandiosis, sporotrichosis, chromoblastomycosis, cryptocosis, mycotic mycetomas, deep dermatophytosis) among allo-SCT patients has remained relatively stable over time, while aspergillosis has decreased slightly (fig 1). The occurrence of FI, medicare as payer status, allo-SCT done prior to the era of newer antifungal agents (2000-2001) and >median length of in-hospital stay were associated with higher IHM among allo-SCT patients (Odds ratio (OR) 4.331, p-value <0.0001, OR 1.359, p-value=0.0145, OR 1.830, p-value =<0.0001, OR 3.017, p-value <0.0001 respectively) (Table 1). On separate analyses, we see that FI are more strongly associated with IHM in 2000-2001 (5.009, p-value <0.001) as compared to 2002-2010 (4.168, p-value <0.001).

Conclusions
While the incidence of various FI among allo-SCT recipients has remained relatively stable over the last decade, the occurrence of FI, medicare as payer status and allo-SCT performed prior to the era of newer anti-fungal agents were both factors associated with higher IHM. Although there is a difference in ORs on separate analyses of the two eras, there is an overlap of confidence intervals (Table 1). This could possibly due to the small sample size. Further studies looking back in time prior to 2000 and looking further ahead in time at delayed FI would possibly assist in making conclusions. While we cannot directly attribute differences in outcome to the use of newer anti-fungal agents, these data suggest that these agents may be having an impact on the survivability of FI in the setting of allo-SCT.

Multivariate analyses adjusting for presence of FI, era of antifungals, gender, length of stay and insurance status

<table>
<thead>
<tr>
<th>Fungal Infection</th>
<th>OR (95% CI)</th>
<th>Pr(ChiSq)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insurance</td>
<td>4.331 (3.650-5.500)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Medicare</td>
<td>1.359 (1.066-1.733)</td>
<td>0.0145</td>
</tr>
<tr>
<td>Others</td>
<td>1.187 (0.950-1.483)</td>
<td>0.2585</td>
</tr>
<tr>
<td>Private</td>
<td>0.821 (0.597-1.128)</td>
<td>0.2073</td>
</tr>
</tbody>
</table>

Multivariate analyses adjusting for presence of FI, gender, length of stay and insurance status in 2000-2001 and in 2002-2010

Keywords
Multiple Myeloma; Stem Cell transplant; Fungal Infection

*Nishi Shah
E-mail: nishi.shah@emory.edu